NeoDynamics carries out a couple of studies in Europe to support their promising Neonavia product and upcoming launch in US.
COMPULSE - Randomized controlled multicentre study.
British study on comparison between NeoNavia (NeoDynamics) and conventional 14G CNB for tissue sampling in axillary lymph nodes (COMPULSE).
Watch the video:
NeoDynamics AB (publ) a Swedish medical technology company dedicated to advancing the diagnostics and treatment of cancer. The company has created an innovative biopsy system called NeoNavia®. This biopsy system builds on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The innovative pulse biopsy system is designed to offer clinicians and patients reliable tissue sampling with high tissue yield for correct diagnosis and individualised treatment. NeoNavia has been launched on the Swedish, German, and British market.
NeoDynamics is listed on Nasdaq First North Growth Market in Stockholm.
Neodynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.
Read more on company page